by Jordana Choucair | Oct 4, 2021 | Public Health/Prevention
Anthony Fauci said the country is “turning the corner” on the latest COVID-19 surge, but that the 70 million eligible people who haven’t been vaccinated remain vulnerable. Fauci also touted the success of Merck & Co.’s experimental...
by Jordana Choucair | Oct 1, 2021 | Transition to Value
CMS Chief Operating Officer Jon Blum said the agency’s innovation center is unlikely to adopt many additional fully risk-based payment models because they tend to “favor those who are better capitalized and can afford risk.” He said CMS wants to...
by Jordana Choucair | Oct 1, 2021 | Public Health/Prevention
A new report from the FDA and CDC found that teen vaping plummeted this year as the COVID-19 pandemic forced many U.S. students to learn from home. In the national survey, 11 percent of high school students and less than 3 percent of middle school students said they...
by Jordana Choucair | Oct 1, 2021 | Payers
HHS issued an interim final rule that outlines how dispute resolution regarding surprise billing should work between out-of-network providers and insurers. The rule states that payers and providers must start with a 30-day “open negotiation” to determine a...
by Jordana Choucair | Oct 1, 2021 | Opioid/Substance Use Disorders
• Four large pharmacy chains are set to face their first trial over the deadly U.S. opioid epidemic. Lawyers for the Ohio counties of Lake and Trumbull and companies – Walgreens Boots Alliance Inc, CVS Health Corp, Walmart Inc, and Giant Eagle Inc – are set to deliver...
by Jordana Choucair | Oct 1, 2021 | Life Sciences
Merck & Co. said its experimental antiviral pill to treat COVID-19 reduced the risk of hospitalization and death by nearly half in a clinical trial. The results prompted an independent monitoring board to recommend the study end early because of the promising...
Recent Comments